11. Myasthenia
226 clinical trials,   172 drugs   (DrugBank: 45 drugs),   43 drug target genes,   118 drug target pathways

Searched query = "Myasthenia", "MG"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02950155
(ClinicalTrials.gov)
October 16, 201628/10/2016A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia GravisA Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Safety and Efficacy of Rituximab (Mabthera®) in Patients With New Onset Generalized Myasthenia Gravis (MG)Generalized Myasthenia GravisDrug: Rituximab;Drug: Sodium Chloride solutionFredrik PiehlNULLActive, not recruiting18 YearsN/AAll47Phase 3Sweden
2EUCTR2015-005749-30-SE
(EUCTR)
23/06/201628/04/2016A clinical trial investigating the effect and safety of the drug rituximab in patients with new onset myasthenia gravis, an autoimmune condition affecting muscle strenghtA randomized, doubleblind, placebo-controlled multicenter trial to evaluate the safety and efficacy of rituximab (Mabthera) in subjects with new onset myasthenia gravis; the RINOMAX study - Rinomax New onset myasthenia gravis
MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Mabthera
INN or Proposed INN: RITUXIMAB
Karolinska InstitutetNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 3Sweden
3JPRN-UMIN000016564
2015/03/1323/02/2015Rituximab for intractable myasthenia gravis myasthenia gravisrituximabTokushima University HospitalNULLPending15years-old80years-oldMale and Female1Not selectedJapan
4NCT02110706
(ClinicalTrials.gov)
May 20147/4/2014BeatMG: Phase II Trial of Rituximab In Myasthenia GravisB Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia GravisMyasthenia GravisDrug: Rituximab;Drug: PlaceboYale UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Completed21 Years90 YearsAll52Phase 2United States
5JPRN-UMIN000012089
2013/10/1523/10/2013Treatment of MuSK antibody-positive myasthenia gravis with rituximab: an exploratory clinical studyTreatment of MuSK antibody-positive myasthenia gravis with rituximab: an exploratory clinical study - Treatment of MuSK antibody-positive myasthenia gravis with rituximab: an exploratory clinical study MuSK antibody-positive myasthenia gravisAdministration of Rituximab at the standard dose of 375 mg/m2 every week for 4 consecutive weeks and then monthly for the next 3 months.Department of NeurologyUniversity of Tokyo, Graduate School of MedicineNULLComplete: follow-up complete20years-old80years-oldMale and Female5Not selectedJapan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00774462
(ClinicalTrials.gov)
January 200816/10/2008Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia GravisFORCE: Rituximab (CD 20+-B Cell-depleting Monoclonal Antibody) for the Treatment of Refractory Inflammatory Myopathies With Specific Antibodies and Refractory Myasthenia GravisMyositis;Myasthenia GravisDrug: RituximabAssistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France;Roche Pharma AGCompleted18 Years80 YearsBoth30Phase 2France
7NCT00619671
(ClinicalTrials.gov)
April 200414/1/2008A Pilot Trial of Rituxan in Refractory Myasthenia GravisPhase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis.Refractory Myasthenia GravisDrug: Rituximab (Rituxan)University of VermontGenentech, Inc.Completed18 Years80 YearsBoth10Phase 1;Phase 2United States